Ketamine’s Therapeutic Role in Substance Use Disorders: A Narrative Review
NeuroSci · 27.08.2025 · 6 (3) · 83
DOI: 10.3390/neurosci6030083 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift NeuroSci, online erschienen am 27.08.2025. Verfasst von Alexander Thomas und 1 weiteren Autor:innen. Beteiligte Einrichtung: Indiana University School of Medicine Addiction Psychiatry Fellowship Program, Goodman Hall, Department of Psychiatry, Indianapolis, IN 46202, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HRSA-AMF.
Abstract (Originalsprache)
Interest in ketamine as a novel treatment for substance use disorders (SUDs) has been increasing due to its N-methyl-D-aspartate (NMDA) glutamate receptor antagonism and mounting evidence that glutamate neurotransmission is involved in the pathogenesis of both depression and addictions. This narrative review provides an outline of clinical evidence reported in the literature from the 1970s to 2025 that examines the efficacy of ketamine for the treatment of SUDs, focusing primarily on randomized blinded controlled trials (RBCTs). Key cohort studies, retrospective studies, secondary analyses, case reports, and relevant basic neuroscience studies are reviewed to complement the more rigorous human controlled trial data. Thus far, ketamine has been tested in nine RBCTs targeting cocaine (three studies), alcohol (three studies), opioid use disorder (two studies), and nicotine (one study), suggesting efficacy for addiction in combination with psychotherapies, and often when doses produce subjectively reported mystical or psychedelic experiences. This review highlights promising preliminary evidence, and the need for more rigorous studies to elucidate the scope of drug addictions ketamine may target, its optimal dosing or route of administration, the importance of concurrent psychotherapies, professional supervision and safety monitoring, and which psychiatric comorbidities or contexts may contraindicate its use for SUDs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Indiana University School of Medicine Addiction Psychiatry Fellowship Program, Goodman Hall, Department of Psychiatry, Indianapolis, IN 46202, USA.
ORCID-Profile: Alexander Thomas
Förderung
- HRSA-AMF
Zitieren
APA
Thomas, A., & Chambers, R. A. (2025). Ketamine’s Therapeutic Role in Substance Use Disorders: A Narrative Review. NeuroSci, 6(3), 83. https://doi.org/10.3390/neurosci6030083
Vancouver
Thomas A, Chambers RA. Ketamine’s Therapeutic Role in Substance Use Disorders: A Narrative Review. NeuroSci. 2025;6(3):83. doi:10.3390/neurosci6030083
BibTeX
@article{Thomas2025,
author = {Thomas, Alexander and Chambers, R Andrew},
title = {Ketamine’s Therapeutic Role in Substance Use Disorders: A Narrative Review},
journal = {NeuroSci},
year = {2025},
volume = {6},
number = {3},
pages = {83},
doi = {10.3390/neurosci6030083}
}
EUVIMED